Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA‐SRVTrial
This is the first study, to our knowledge, demonstrating the functional benefits and safety of dapagliflozin in symptomatic patients with sRV dysfunction under medical treatment with sacubitril/valsartan. These results support the need for larger randomized trials to further evaluate this therapeutic option in this population.
Authors
- Victor Waldmann (ORCID: https://orcid.org/0000-0001-8057-1900)
- Laurence Iserin
- Magalie Ladouceur (ORCID: https://orcid.org/0000-0002-4325-3521)
- Ana Barat (ORCID: https://orcid.org/0000-0001-7164-5322)
- Mathieu Albertini (ORCID: https://orcid.org/0000-0002-8082-2439)
- Antoine Legendre (ORCID: https://orcid.org/0000-0002-8374-1490)
- Anne‐Solene Chaussade
- P. David
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Hôpital Européen Georges-Pompidou (FR)
- University Hospital of Geneva (CH)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1161/jaha.124.040302
- Citations
- 10
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 13.88